AZ’ lung cancer drug Tagrisso bags breakthrough status
AstraZeneca | October 10, 2017
AstraZeneca’s Tagrisso has been awarded breakthrough status in the US as a first-line treatment for a specific type of non-small cell lung cancer (NSCLC), potentially speeding up its development and regulatory pathway.